Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Amarin Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Amarin and HLS Therapeutics Enter into Agreement 11
Amarin Enters into Development Agreement with Eddingpharm 12
Amarin And Kowa Pharm Enter Into Co-Promotion Agreement For Vascepa Capsules 13
Equity Offering 15
Amarin Files Registration Statement for Public Offering of ADS 15
Amarin Announces Underwriter’s Exercise of Over-Allotment Option of Public Offering of ADS for USD69 Million 16
Amarin to Raise USD53 Million in Private Placement of American Depositary Shares 18
Amarin Completes Public Offering Of Shares For US$121.5 Million 19
Amarin Completes An Underwritten Public Offering Of US$105 Million 21
Debt Offering 23
Corsicanto II Designated Activity (Amarin) Raises USD30 Million in Exchangeable Senior Notes 23
Amarin to Raise USD31.3 Million in Private Placement of 3.5% Notes Due 2032 24
Amarin Corporation Completes Private Placement For US$100 Million 25
Amarin Completes Private Placement Of 3.5% Exchangeable Senior Notes Due 2032 For US$150 Million 26
Acquisition 27
Teva Pharma Rumored To Acquire Amarin 27
Amarin Corp Plc – Key Competitors 28
Amarin Corp Plc – Key Employees 29
Amarin Corp Plc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Nov 01, 2017: Amarin Reports Third Quarter 2017 Financial Results and Provides Update on Operations 31
Aug 02, 2017: Amarin Reports Second Quarter 2017 Financial Results and Provides Update on Operations 33
May 03, 2017: Amarin reports lower Q1 net loss, re-affirms annual guidance 36
Feb 28, 2017: Amarin Reports Record Fourth Quarter and Full Year 2016 Financial Results and Provides Update on Operations 37
Jan 05, 2017: Amarin announces revenue forecast for 2017 40
Jan 05, 2017: Amarin Provides Preliminary 2016 Results and 2017 Outlook 42
Nov 03, 2016: Amarin Reports Third Quarter 2016 Financial Results and Provides Update on Operations 44
Aug 04, 2016: Amarin Reports Second Quarter 2016 Financial Results and Provides Update on Operations 47
May 05, 2016: Amarin Reports First Quarter 2016 Financial Results and Provides Update on Operations 50
Feb 25, 2016: Amarin Reports Fourth Quarter and Year-End 2015 Financial Results and Provides Update on Operations 52
Jan 11, 2016: Amarin Reports Preliminary 2015 Net Product Sales and Provides 2016 Revenue and Business Outlook 56
Corporate Communications 58
Jun 30, 2016: Amarin Appoints Michael W. Kalb Chief Financial Officer 58
Jan 21, 2016: Amarin Appoints Craig B. Granowitz Chief Medical Officer and Names Steven Ketchum Chief Scientific Officer 59
Legal and Regulatory 60
Mar 09, 2016: Court Approves Proposed Settlement Terms in Amarin First Amendment Litigation 60
Feb 17, 2016: Request for Continued Stay in Court Proceedings Submitted in Amarin First Amendment Litigation 61
Product News 62
11/14/2016: Pure EPA Vascepa (icosapent ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Parameters in Statin-Treated Women with Persistent High Triglycerides 62
10/25/2016: Pure EPA Vascepa Now Available in New, Smaller Half-Gram Capsule Size 64
06/12/2017: Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Women With Type 2 Diabetes and Persistent High Triglycerides 65
06/11/2016: Vascepa(R) (Icosapent Ethyl) Showed Significant Reductions in Potentially Atherogenic Lipid Parameters in Statin-Treated Patients With Type 2 Diabetes and Persistent High Triglycerides 66
06/06/2016: Vascepa (Icosapent Ethyl) Data to Be Presented at American Diabetes Association 76th Scientific Sessions 68
05/20/2016: Vascepa (Icosapent Ethyl) Showed Significant Reductions in Key Lipid Parameters in Subgroup of Women With Very High Triglyceride Levels 69
05/18/2017: Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care 70
05/11/2016: Vascepa (icosapent ethyl) and Eicosapentaenoic Acid (EPA) Data to Be Presented at National Lipid Association 2016 Scientific Sessions 71
05/03/2017: Amarin Reports First Quarter 2017 Financial Results and Provides Update on Operations 72
03/16/2017: Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study 77
03/15/2017: Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology 78
03/08/2016: Amarin’s Right to Promote Vascepa Off-Label Affirmed Under First Amendment Litigation Settlement Terms 79
01/05/2017: Amarin Provides Preliminary 2016 Results and 2017 Outlook 81
Clinical Trials 83
Sep 13, 2017: Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer 83
Aug 14, 2017: Amarin Provides Update on Vascepa 84
Sep 12, 2016: Amarin’s REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee 86
Aug 31, 2016: Amarin Randomizes Final Patient into REDUCE-IT Cardiovascular Outcomes Study of Vascepa 87
Aug 04, 2016: Amarin and FDA Reaffirm Concurrence on REDUCE-IT Through Special Protocol Assessment Agreement Amendment 88
Apr 04, 2016: Amarin Corporation Presents Pre-Clinical Data at American College of Cardiology Meeting on the Effect of EPA Therapy on Endothelial Function 91
Apr 04, 2016: New Clinical Data Presented on Vascepa at American College of Cardiology Meeting on the Effect of EPA Therapy in Statin-Treated Patients in Exploratory Studies 92
Mar 31, 2016: Amarin Reaches Target Enrollment in Cardiovascular Outcomes Study of Vascepa in Patients With Elevated Triglycerides Despite Statin Therapy 94
Appendix 96
Methodology 96
About GlobalData 96
Contact Us 96
Disclaimer 96
Amarin Corp Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Amarin Corp Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Amarin Corp Plc, Deals By Therapy Area, 2011 to YTD 2017 9
Amarin Corp Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Amarin and HLS Therapeutics Enter into Agreement 11
Amarin Enters into Development Agreement with Eddingpharm 12
Amarin And Kowa Pharm Enter Into Co-Promotion Agreement For Vascepa Capsules 13
Amarin Files Registration Statement for Public Offering of ADS 15
Amarin Announces Underwriter’s Exercise of Over-Allotment Option of Public Offering of ADS for USD69 Million 16
Amarin to Raise USD53 Million in Private Placement of American Depositary Shares 18
Amarin Completes Public Offering Of Shares For US$121.5 Million 19
Amarin Completes An Underwritten Public Offering Of US$105 Million 21
Corsicanto II Designated Activity (Amarin) Raises USD30 Million in Exchangeable Senior Notes 23
Amarin to Raise USD31.3 Million in Private Placement of 3.5% Notes Due 2032 24
Amarin Corporation Completes Private Placement For US$100 Million 25
Amarin Completes Private Placement Of 3.5% Exchangeable Senior Notes Due 2032 For US$150 Million 26
Teva Pharma Rumored To Acquire Amarin 27
Amarin Corp Plc, Key Competitors 28
Amarin Corp Plc, Key Employees 29
Amarin Corp Plc, Subsidiaries 30
